However, within the context of PSMA PET/CT imaging for prostate cancer, prior studies following the VISION trial primarily focused on the prognostic value of semi-quantitative parameters such as SUVmean [25,26,27]. The gene discussed is FOLH1; the disease is prostate cancer.